Clinical Trial Update: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Sponsored by AbbVie, the Phase 3 trial is evaluating intravenous Etentamig as monotherapy versus standard therapies in adults with relapsed or refractory multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Etentamig

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING